Targeting Cardiovascular Disease in Patients with Chronic Kidney Disease: Is Primary Prevention with Aspirin Ready for Prime Time? Roy O. MathewElvira O. GosmanovaMandeep S. Sidhu EDITORIAL 19 June 2018 Pages: 241 - 243
Ischaemic Preconditioning Protects Cardiomyocytes from Anthracycline-Induced Toxicity via the PI3K Pathway Angshuman MaulikSean M. DavidsonDerek M. Yellon ORIGINAL ARTICLE Open access 15 May 2018 Pages: 245 - 253
Aspirin for Primary Prevention of Cardiovascular Disease and Renal Disease Progression in Chronic Kidney Disease Patients: a Multicenter Randomized Clinical Trial (AASER Study) Marian GoicoecheaSoledad García de VinuesaJosé Luño ORIGINAL ARTICLE 08 June 2018 Pages: 255 - 263
A 10-Year Trend in Statin Use Among Older Adults in Australia: an Analysis Using National Pharmacy Claims Data Richard Ofori-AsensoJenni IlomäkiDanny Liew ORIGINAL ARTICLE 23 May 2018 Pages: 265 - 272
Statin Utilization Patterns and Outcomes for Patients with Acute Coronary Syndrome During and Following Inpatient Admissions Susan H. BoklageElisabetta Malangone-MonacoJoseph Elassal ORIGINAL ARTICLE Open access 31 May 2018 Pages: 273 - 280
Target Population of Non-deferrable Surgery and Uncontrolled Severe Bleeding Related to Dabigatran Silvia CalabriaEmanuele ForcesiNello Martini SHORT COMMUNICATION 04 June 2018 Pages: 281 - 286
Ticagrelor Versus Clopidogrel as Part of Dual or Triple Antithrombotic Therapy: a Systematic Review and Meta-Analysis Ioannis AndreouAlexandros BriasoulisDimitrios Alexopoulos ORIGINAL ARTICLE 15 May 2018 Pages: 287 - 294
Assessment of Complementary Treatment with Yiqi Fumai Lyophilized Injection on Acute Decompensated Ischemic Heart Failure (ACT-ADIHF): Rationale and Design of a Multicenter, Randomized, Controlled Trial Xianliang WangZhiqiang ZhaoBoli Zhang ORIGINAL ARTICLE 30 April 2018 Pages: 295 - 300
Systematic Review of Methods Used for the Microvascular Assessment of Peripheral Arterial Disease Qinzhong ChenRobert S. Rosenson REVIEW ARTICLE 29 May 2018 Pages: 301 - 310
Effect of Anagliptin and Sitagliptin in Type 2 Diabetic Patients with Dyslipidemia and Cardiovascular Risk: What Is the Real REASON Behind It? Venu Gopal JonnalagaddaHarish Prabhanna CharPraveen Kumar Ankana LETTER TO THE EDITOR 07 March 2018 Pages: 311 - 311